Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Federal Circuit
Innovation Toys And Analogous Art – Defender Against Hindsight?
There is nothing particularly surprising in the recent Fed. Cir. decision of Innovation Toys v. MGA Entertainment, App. No. 2010-1290 (Fed. Cir. March 21, 2011) (a copy is available at the end of this post), which reversed a District Court finding … Continue reading
Siemens v. Saint-Gobain – What’s Sauce For The Goose May Leave The Gander Unscathed
Contributed by Jim Nelson, J.D., Ph.D. of Schwegman Lundberg & Woessner, P.A. The Siemens Medical Solutions USA, Inc. v. Saint-Gobain Ceramics & Plastics, Inc., (a copy is available at the end of this post) case presents a fundamental issue and … Continue reading
Happy Birthday Patents4Life – We Are 2!
Now some of them are not yet carved in judicial stone, being at various stages of appeal, but the sum of KSR, Bilski (well, I guess it was more pro-patent than the strict M or T test it replaced with … Continue reading
Posted in About SLW
Tagged Ariad, Ariad v. Lilly, Bilski, biotechnology, biotechnology law, biotechnology news, Federal Circuit, intellectual property, ip, IP law tools, KSR, Kubin, Lilly, Myriad, Patent Law, patents, Pharmaceutical law, Prometheus v. Mayo, stem cells, Supreme Court, Warren Woessner
1 Comment
Centocor v. Abbott: Fed. Cir. Takes New Written Description Requirement Out For A Spin.
In an important post-Ariad decision, the Federal Circuit reversed a district court decision that Abbott’s Humira infringed claims of a Centocor patent that could have cost Abbott $1.67 billion in damages. (A copy of the decision is at the end … Continue reading